{
    "relation": [
        [
            "",
            "Erlotinib HCl + Bevacizumab",
            "Erlotinib HCl + Placebo"
        ],
        [
            "Description",
            "oral erlotinib HCl 150 mg/day orally + intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle",
            "oral erlotinib HCl 150 mg/day orally + intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle"
        ]
    ],
    "pageTitle": "A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00130728?sect=X0125&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042990609.0/warc/CC-MAIN-20150728002310-00303-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 858751877,
    "recordOffset": 858735939,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: bevacizumab Drug: erlotinib HCl Drug: placebo Interventions: Non-Small Cell Lung Cancer Condition: Allocation:\u00a0Randomized; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Investigator); \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type: Results First Received: November 16, 2009 \u00a0",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Erlotinib HCl + Bevacizumab \u00a0 \u00a0 Erlotinib HCl + Placebo \u00a0 STARTED \u00a0 \u00a0 319 \u00a0 \u00a0 317 \u00a0 Received Study Drug (Safety Population) \u00a0 \u00a0 313 \u00a0 \u00a0 313 \u00a0 COMPLETED \u00a0 \u00a0 108 \u00a0 \u00a0 104 \u00a0 NOT COMPLETED \u00a0 \u00a0 211 \u00a0 \u00a0 213 \u00a0 Death \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 207 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 211 \u00a0 Lost to Follow-up \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 4 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}